NasdaqGS:INCYBiotechs
A Fresh Look at Incyte (INCY) Valuation Following Upbeat Analyst Upgrades and 2025 Guidance Boost
Incyte (INCY) grabbed investors’ attention this week after a major investment firm upgraded its view on the stock, following the company’s strong third quarter earnings report and a boost in its 2025 revenue guidance. Higher demand for Jakafi and other hematology products has played a key role in the company’s improved outlook.
See our latest analysis for Incyte.
Incyte’s momentum has only picked up over the past year, with the share price climbing 52.4% year-to-date and a 35.2% jump just in...